Literature DB >> 16601431

The clinicopathologic significance of the expression of vascular endothelial growth factor-C in intrahepatic cholangiocarcinoma.

Byung Kyu Park1, Yong-Han Paik, Jeong Youp Park, Kyung Hwa Park, Seungmin Bang, Seung Woo Park, Jae Bock Chung, Young Nyun Park, Si Young Song.   

Abstract

OBJECTIVES: Vascular endothelial growth factor-C (VEGF-C) is known to be an important lymphangiogenetic factor. Lymphatic spread is a key prognostic factor in intrahepatic cholangiocarcinoma (ICC). We studied the expression of VEGF-C in ICC tissues to clarify its clinicopathologic significance.
METHODS: The expression of VEGF-C in surgical specimens obtained from 36 patients with ICC who underwent hepatic resection was examined by immunohistochemistry and Western blotting. Strong staining was defined as the presence of VEGF-C immunoreactivity in at least 50% of the tumor cells. Immunoreactivity in approximately 10% to approximately 50% of the tumor cells was considered as weak staining, and less than 10% as no staining.
RESULTS: Of the 36 patients with ICC, 15 patients (41.7%) showed a strong positive result for VEGF-C. Eleven cases (30.6%) were negative and 10 cases (27.8%) showed weak immunoreactivity. VEGF-C expression was significantly correlated with lymph node metastasis (P = 0.032) and positive surgical margin (P = 0.03). Patients who had strong positive staining for VEGF-C showed significantly less favorable survival rates compared with patients who had negative or weak staining (P < 0.01). Other significant prognostic factors by univariate analysis were vascular invasion, lymph node involvement, and positive surgical margin. Multivariate analysis demonstrated that strong VEGF-C expression (P = 0.028) and vascular invasion (P = 0.021) were independent factors indicating poor prognosis.
CONCLUSIONS: Our data suggest that VEGF-C expression serves as an independent and important prognostic factor in ICC patients, and it may play an important role in the lymph node metastasis of ICC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16601431     DOI: 10.1097/01.coc.0000204402.29830.08

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  32 in total

Review 1.  Hypoxic tumor microenvironment: Implications for cancer therapy.

Authors:  Sukanya Roy; Subhashree Kumaravel; Ankith Sharma; Camille L Duran; Kayla J Bayless; Sanjukta Chakraborty
Journal:  Exp Biol Med (Maywood)       Date:  2020-06-27

2.  Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.

Authors:  Sam J Lubner; Michelle R Mahoney; Jill L Kolesar; Noelle K Loconte; George P Kim; Henry C Pitot; Philip A Philip; Joel Picus; Wei-Peng Yong; Lisa Horvath; Guy Van Hazel; Charles E Erlichman; Kyle D Holen
Journal:  J Clin Oncol       Date:  2010-06-07       Impact factor: 44.544

3.  Results of a phase I-II study on intraductal confocal microscopy (IDCM) in patients with common bile duct (CBD) stenosis.

Authors:  M Giovannini; E Bories; G Monges; C Pesenti; F Caillol; J R Delpero
Journal:  Surg Endosc       Date:  2011-03-18       Impact factor: 4.584

Review 4.  Targeted medical therapy of biliary tract cancer: recent advances and future perspectives.

Authors:  Michael Hopfner; Detlef Schuppan; Hans Scherubl
Journal:  World J Gastroenterol       Date:  2008-12-14       Impact factor: 5.742

5.  A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.

Authors:  Lipika Goyal; Hui Zheng; Matthew B Yurgelun; Thomas A Abrams; Jill N Allen; James M Cleary; Michelle Knowles; Eileen Regan; Amanda Reardon; Anna Khachatryan; Rakesh K Jain; Valentina Nardi; Darrell R Borger; Dan G Duda; Andrew X Zhu
Journal:  Cancer       Date:  2017-02-13       Impact factor: 6.860

6.  Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy.

Authors:  Chantal Dreyer; Marie-Paule Sablin; Mohamed Bouattour; Cindy Neuzillet; Maxime Ronot; Safi Dokmak; Jacques Belghiti; Nathalie Guedj; Valérie Paradis; Eric Raymond; Sandrine Faivre
Journal:  World J Hepatol       Date:  2015-04-28

Review 7.  Biomarkers in bile-complementing advanced endoscopic imaging in the diagnosis of indeterminate biliary strictures.

Authors:  Vennisvasanth Lourdusamy; Benjamin Tharian; Udayakumar Navaneethan
Journal:  World J Gastrointest Endosc       Date:  2015-04-16

8.  A perspective on molecular therapy in cholangiocarcinoma: present status and future directions.

Authors:  Jesper B Andersen; Snorri S Thorgeirsson
Journal:  Hepat Oncol       Date:  2014-01-01

9.  Expression of matrix metalloproteinase 2 and extracellular matrix metalloproteinase inducer are unfavorable postoperative prognostic factors in intrahepatic cholangiocarcinoma.

Authors:  Che Zhang; Ziliang Tu; Shiming Du; Yong Wang; Qibin Wang
Journal:  Pathol Oncol Res       Date:  2009-07-25       Impact factor: 3.201

Review 10.  Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies.

Authors:  D Sia; V Tovar; A Moeini; J M Llovet
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.